Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer
Author(s) -
Satoshi Kobayashi,
Motoko Suzuki,
Makoto Ueno,
Yuta Maruki,
Naohiro Okano,
Akiko Todaka,
Masato Ozaka,
Kunihiro Tsuji,
Kazuhiko Shioji,
Keitaro Doi,
Yasushi Kojima,
Hidetaka Tsumura,
Kazunari Tanaka,
Hajime Higuchi,
Ken Kawabe,
Hiroshi Imaoka,
Tatsuya Yamashita,
Haruo Miwa,
Hiroaki Nagano,
Shiho Arima,
Hideyuki Hayashi,
Atsushi Naganuma,
Hironori Yamaguchi,
Terumasa Hisano,
Kumiko Umemoto,
Shuji Ishii,
Koji Nakashima,
Rei Suzuki,
Yohei Kitano,
Toshihiro Misumi,
Junji Furuse,
Hiroshi Ishii
Publication year - 2022
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1093/oncolo/oyac157
Subject(s) - medicine , gemcitabine , hazard ratio , adverse effect , incidence (geometry) , propensity score matching , pancreatic cancer , observational study , cancer , oncology , confidence interval , physics , optics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom